GSK - Tonix Trial Update And Other News: The Good Bad And Ugly Of Biopharma
Tonix Goes Ahead with Late Stage Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (TNXP) announced that it has hit 50 percent enrollment milestone for its Phase 3 RELIEF trial. The trial will incorporate a pivotal study of TNX-102 SL 5.6 mg for managing fibromyalgia. The drug candidate is a centrally acting analgesic and is designed to be taken daily at bedtime. The company plans to carry out an interim analysis of the first 50 percent of randomized participants shortly after the completion of the 12-week treatment period.
Tonix Pharmaceuticals reported that subject to the approval